DE60018833D1 - Verfahren zur Synthese von Nukleosidanaloga - Google Patents

Verfahren zur Synthese von Nukleosidanaloga

Info

Publication number
DE60018833D1
DE60018833D1 DE60018833T DE60018833T DE60018833D1 DE 60018833 D1 DE60018833 D1 DE 60018833D1 DE 60018833 T DE60018833 T DE 60018833T DE 60018833 T DE60018833 T DE 60018833T DE 60018833 D1 DE60018833 D1 DE 60018833D1
Authority
DE
Germany
Prior art keywords
synthesis
nucleoside analogues
nucleoside
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018833T
Other languages
German (de)
English (en)
Inventor
Robert William Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60018833D1 publication Critical patent/DE60018833D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60018833T 1999-05-11 2000-05-09 Verfahren zur Synthese von Nukleosidanaloga Expired - Lifetime DE60018833D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
DE60018833D1 true DE60018833D1 (de) 2005-04-28

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018833T Expired - Lifetime DE60018833D1 (de) 1999-05-11 2000-05-09 Verfahren zur Synthese von Nukleosidanaloga

Country Status (22)

Country Link
US (1) US6271370B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1052264B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2001011092A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100403900B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1275575A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR028991A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE291582T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU3401100A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0002089A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2307951A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ20001710A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60018833D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0001843A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID25992A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL136027A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN186850B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA00004532A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL340109A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2200738C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200001340A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU25500A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200002263B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
KR101236669B1 (ko) * 2004-07-21 2013-02-22 길리어드 파마셋 엘엘씨 알킬-치환된 2-데옥시-2-플루오로-ｄ-리보퓨라노실피리미딘 및 퓨린 및 그 유도체의 제조
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
BRPI0820872A2 (pt) 2007-12-14 2015-07-21 Pulmagen Therapeutics Asthma Ltd Indoles e seu terapêutico.
CA2709176C (en) 2007-12-14 2013-02-05 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
JP2012517992A (ja) 2009-02-17 2012-08-09 チェシ ファーマスーティシ エス．ピー．エイ． Ｐ３８ｍａｐキナーゼインヒビターとしてのトリアゾロピリジン誘導体
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
IN2012DN01453A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-08-20 2015-06-05 Novartis Ag
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
GEP201706735B (en) 2011-12-09 2017-09-25 Chiesi Farm Spa Kinase inhibitors
AU2012347352B2 (en) 2011-12-09 2016-12-15 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
BR112015029970A2 (pt) 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
KR20160050080A (ko) 2013-09-05 2016-05-10 에프. 호프만-라 로슈 아게 트라이아졸로피리딘 화합물, 이의 조성물 및 사용 방법
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
JP2018507236A (ja) 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
MA46176A (fr) 2016-09-06 2019-07-17 Hoffmann La Roche Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci
RU2019123319A (ru) 2016-12-29 2021-02-01 Ф. Хоффманн-Ля Рош Аг Пиразолопиримидины и способы их применения
EP3596072B1 (en) 2017-03-14 2022-06-22 F. Hoffmann-La Roche AG Pyrazolochlorophenyl compounds, compositions and methods of use thereof
TW201900648A (zh) 2017-05-22 2019-01-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及組成物以及其使用方法
EP3630766A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
JP2021525802A (ja) 2018-06-01 2021-09-27 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Ｐｉ３ｋに関連する疾患または障害に対する併用療法
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
JP7716993B2 (ja) 2019-06-18 2025-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
MA56518A (fr) 2019-06-18 2022-04-27 Hoffmann La Roche Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
KR19990081940A (ko) 1996-01-23 1999-11-15 그레이엄 브레레톤, 레슬리 에드워즈 항바이러스제로서 변형된 벤즈이미다졸 누클레오시드

Also Published As

Publication number Publication date
TR200001340A2 (tr) 2000-12-21
PL340109A1 (en) 2000-11-20
IN186850B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-11-24
HUP0001843A2 (hu) 2001-06-28
RU2200738C2 (ru) 2003-03-20
ZA200002263B (en) 2001-12-24
BR0002089A (pt) 2001-01-02
EP1052264A2 (en) 2000-11-15
AR028991A1 (es) 2003-06-04
EP1052264A3 (en) 2001-06-13
IL136027A0 (en) 2001-05-20
MXPA00004532A (es) 2002-03-08
US6271370B1 (en) 2001-08-07
ID25992A (id) 2000-11-16
EP1052264B1 (en) 2005-03-23
JP2001011092A (ja) 2001-01-16
HU0001843D0 (en) 2000-07-28
CA2307951A1 (en) 2000-11-11
HUP0001843A3 (en) 2001-09-28
ATE291582T1 (de) 2005-04-15
CN1275575A (zh) 2000-12-06
KR20010069193A (ko) 2001-07-23
AU3401100A (en) 2000-11-16
YU25500A (sh) 2003-08-29
CZ20001710A3 (cs) 2001-09-12
KR100403900B1 (ko) 2003-11-01

Similar Documents

Publication Publication Date Title
DE60018833D1 (de) Verfahren zur Synthese von Nukleosidanaloga
EP1066308A4 (en) IMPROVED METHODS OF SYNTHESIS OF OLIGONUCLEOTIDES
EP1427743A4 (en) SYNTHESIS OF PYRAZOLOPYRIMIDINES
DE50015014D1 (de) Verfahren zur Hydroformylierung von Olefinen
DE60114525D1 (de) Array-basierende Methoden zur Synthese von Nukleinsäuregemischen
DE50015005D1 (de) Verfahren zur katalytischen Durchführung von Hydroformylierungen
DE60221619D1 (de) Verfahren zur Reinigung von Synthesegas
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60008315D1 (de) Verfahren zur Herstellung von Methylchlorid
DE59901861D1 (de) Verfahren zur katalytischen zersetzung von n 2?o
DE69819998D1 (de) Verfahren zur chemischen Synthese von Oligonukleotiden
EP0979233A4 (en) Method for solution phase synthesis of oligonucleotides
DE50014421D1 (de) Verfahren zur Hydrierung von Aceton
DE60201384D1 (de) Verfahren zur Synthese von Harnstoff
DE60108668D1 (de) Verfahren zur herstellung von phenethylamin-derivaten
DE60028076D1 (de) Verfahren zur stereoselektiven synthese zyklischer aminosäuren
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE69824366D1 (de) Verfahren zur Synthese von Alkylpolyglucosiden
DE60111808D1 (de) Verfahren zur Entfernung von Katalysatorresten
DE60112515D1 (de) Verfahren zur Disproportionierung von Isopentan
DE60019606D1 (de) Verfahren zur herstellung von substituierten pyrimidinen
DE59900737D1 (de) Verfahren zur Synthese von Feststoffen
DE69709303D1 (de) Verfahren zur Synthese von Diamant
DE69817550D1 (de) Verfahren zur sprachsynthese
DE60143437D1 (de) Katalytisches verfahren zur herstellung von thiazolderivaten

Legal Events

Date Code Title Description
8332 No legal effect for de